Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT04506086 · Amgen · PHASE4 · terminated · last registry update 2025-05-18 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD3E in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-03-17Phase 3 first posted: Charite University, Berlin, Germany, Inotuzumab ozogamicin (INO) + Blinatumomab (NCT07476729)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2025-12-22Phase 3 first posted: Bambino Gesù Hospital and Research Institute, Ruxolitinib + Blinatumomab (NCT07297914)
- 2025-10-31Phase 3 first posted: Amgen, Blinatumomab + Blinatumomab (NCT07223190)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
- 2025-01-08Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab (Group A) + Venetoclax (nonRand Group) (NCT06764238)
- 2024-10-16Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Ipilimumab (NCT02879695)
- 2024-09-24Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision